Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
173.8 SEK | +2.48% |
|
+3.45% | +29.99% |
Apr. 25 | Transcript : Biotage AB, Q1 2024 Earnings Call, Apr 25, 2024 | |
Apr. 25 | Biotage AB Approves a Dividend, Payable on May 3, 2024 | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The company returns high margins, thereby supporting business profitability.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- With an expected P/E ratio at 53.35 and 38.64 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+29.99% | 1.32B | B+ | ||
-56.07% | 2.17B | C+ | ||
+19.09% | 1.88B | - | ||
-12.63% | 1.45B | - | ||
+8.32% | 853M | - | ||
-30.60% | 799M | - | ||
-36.50% | 726M | - | C- | |
+29.48% | 622M | C+ | ||
-29.02% | 594M | B+ | ||
-9.12% | 298M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- BIOT Stock
- Ratings Biotage AB